163 related articles for article (PubMed ID: 34347376)
1. Screening and identification of potential novel lipid biomarkers for non-small cell lung cancer using ultra-high performance liquid chromatography tandem mass spectrometry.
Han YS; Shi LY; Chen JX; Chen J; Li ZB; Lu QQ; Zhang SQ; Liu J; Yi WJ; Jiang TT; Li JC; Huang J
Anat Rec (Hoboken); 2022 May; 305(5):1087-1099. PubMed ID: 34347376
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential lipid biomarkers for active pulmonary tuberculosis using ultra-high-performance liquid chromatography-tandem mass spectrometry.
Han YS; Chen JX; Li ZB; Chen J; Yi WJ; Huang H; Wei LL; Jiang TT; Li JC
Exp Biol Med (Maywood); 2021 Feb; 246(4):387-399. PubMed ID: 33175608
[TBL] [Abstract][Full Text] [Related]
3. Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients.
Noreldeen HAA; Du L; Li W; Liu X; Wang Y; Xu G
J Pharm Biomed Anal; 2020 Jun; 185():113220. PubMed ID: 32145537
[TBL] [Abstract][Full Text] [Related]
4. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer.
Xiang C; Jin S; Zhang J; Chen M; Xia Y; Shu Y; Guo R
Int J Biol Markers; 2018 Aug; 33(3):314-320. PubMed ID: 29896992
[TBL] [Abstract][Full Text] [Related]
5. Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer.
Chen Y; Ma Z; Shen X; Li L; Zhong J; Min LS; Xu L; Li H; Zhang J; Dai L
Biomed Res Int; 2018; 2018():5276240. PubMed ID: 30175133
[TBL] [Abstract][Full Text] [Related]
6. Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.
Zhang Y; Cheng Y; Qin L; Liu Y; Huang S; Dai L; Tao J; Pan J; Su C; Zhang Y
Int J Biol Markers; 2023 Mar; 38(1):37-45. PubMed ID: 36377344
[TBL] [Abstract][Full Text] [Related]
7. Detection and verification of coexisting diagnostic markers in plasma and serum of patients with non-small-cell lung cancer.
Yu M; Sun R; Zhao Y; Shao F; Zhu W; Aa J
Future Oncol; 2021 Nov; 17(32):4355-4369. PubMed ID: 34674559
[TBL] [Abstract][Full Text] [Related]
8. Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
Li J; Liu K; Ji Z; Wang Y; Yin T; Long T; Shen Y; Cheng L
Cancer Sci; 2023 Feb; 114(2):680-689. PubMed ID: 36310111
[TBL] [Abstract][Full Text] [Related]
9. Assessment of plasma amino acids, purines, tricarboxylic acid cycle metabolites, and lipids levels in NSCLC patients based on LC-MS/MS quantification.
Cang S; Liu R; Mu K; Tang Q; Cui H; Bi K; Zhang Y; Li Q
J Pharm Biomed Anal; 2022 Nov; 221():114990. PubMed ID: 36208488
[TBL] [Abstract][Full Text] [Related]
10. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.
Jin Y; Wang J; Ye X; Su Y; Yu G; Yang Q; Liu W; Yu W; Cai J; Chen X; Liang Y; Chen Y; Wong BH; Fu X; Sun H
Br J Cancer; 2016 Mar; 114(5):532-44. PubMed ID: 26908325
[TBL] [Abstract][Full Text] [Related]
11. Serum Metabolomics Study of Nonsmoking Female Patients with Non-Small Cell Lung Cancer Using Gas Chromatography-Mass Spectrometry.
Mu Y; Zhou Y; Wang Y; Li W; Zhou L; Lu X; Gao P; Gao M; Zhao Y; Wang Q; Wang Y; Xu G
J Proteome Res; 2019 May; 18(5):2175-2184. PubMed ID: 30892048
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum amino acid levels in non-small cell lung cancer: a case-control study in Chinese population.
Liu K; Li J; Long T; Wang Y; Yin T; Long J; Shen Y; Cheng L
PeerJ; 2022; 10():e13272. PubMed ID: 35469201
[TBL] [Abstract][Full Text] [Related]
13. [Nontargeted lipidomic analysis of sera from sepsis patients based on ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry].
Wang S; Liang J; Shi H; Xia Y; Li J; Wu W; Wang H; Wu W
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Apr; 34(4):346-351. PubMed ID: 35692196
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
15. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer.
Cheng F; Wen Z; Feng X; Wang X; Chen Y
Life Sci; 2020 Nov; 260():118489. PubMed ID: 32976882
[TBL] [Abstract][Full Text] [Related]
16. Roles of Lipid Profiles in Human Non-Small Cell Lung Cancer.
Jianyong Z; Yanruo H; Xiaoju T; Yiping W; Fengming L
Technol Cancer Res Treat; 2021; 20():15330338211041472. PubMed ID: 34569862
[No Abstract] [Full Text] [Related]
17. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.
Maeda J; Higashiyama M; Imaizumi A; Nakayama T; Yamamoto H; Daimon T; Yamakado M; Imamura F; Kodama K
BMC Cancer; 2010 Dec; 10():690. PubMed ID: 21176209
[TBL] [Abstract][Full Text] [Related]
18. Serum lipidomic profiling by UHPLC-MS/MS may be able to detect early-stage endometrial cancer.
Cheng F; Fan W; Gui L; Liu Y; Ling Y; Huang R; Wen Z; Chen Y
Anal Bioanal Chem; 2023 Apr; 415(10):1841-1854. PubMed ID: 36799979
[TBL] [Abstract][Full Text] [Related]
19. Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics.
Li W; Wang X; Zhang X; Gong P; Ding D; Wang N; Wang Z
Lipids Health Dis; 2021 Nov; 20(1):160. PubMed ID: 34774030
[TBL] [Abstract][Full Text] [Related]
20. MALDI-TOF-MS analysis in low molecular weight serum peptidome biomarkers for NSCLC.
Song Y; Xu X; Wang N; Zhang T; Hu C
J Clin Lab Anal; 2022 Apr; 36(4):e24254. PubMed ID: 35212031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
